

Brattleboro Memorial Hospital Antimicrobial Susceptibility Report

Urine: Gram-Positive Cocci

	Tested	Year										
			Ampicillin	Benzylpenicillin	Ciprofloxacin	Gentamicin	Nitrofurantoin	Oxacillin	Penicillin	Tetracycline	TMP-SMX	Vancomycin
S. aureus	27	2025	-	0	85.2	100	100	100	0	100	-	100
	19	2024	-	0	73.7	100	100	100	0	94.1	-	100
MRSA	29	2025	-	3	17.2	100	96.6	0	0	92.9	41.4	100
	15	2024	-	0	26.7	100	92.3	0	0	100	53.3	100
S. epidermidis	36	2025	-	3	50	91.7	100	47.2	0	83.3	52.8	100
	39	2024	-	0	61.5	94.9	100	46.2	0	76.9	43.6	100
E. faecalis	114	2025	100	100	86	Gent HS	Linezolid	Strepto HS	100	33.9	-	100
	113	2024	100	100	85.6				100	25.9	-	98.2
E. faecium	1	2025	0	0	100	Gent HS	Linezolid	Strepto HS	0	0	-	100
	8	2024	12.5	12.5	12.5				12.5	28.6	-	87.5
VRE	15	2025	44	43	0	100	100	100	44	0	-	0
	8	2024	25	25	12.5	86	100	100	25	0	-	0

Urine: Gram-Negative Rods

	Tested	Year														
			Ampicillin	Amp-Sulb	Cefazolin	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin	Imipenem	Meropenem	Levofloxacin	Nitrofurantoin	Pip-Tazo	Tobramycin	TMP-SMX
E. coli	784	2025	64.8	74.7	89.7	95.3	83.2	100	92.2	99.5	99.5	83.8	97.4	96.1	93.3	83.4
	751	2024	70	79.8	91.2	93.5	87.2	-	95.2	99.6	99.6	87.2	96.4	92.9	96.7	84.7
E. cloacae complex	44	2025	-	-	0	82.4	93.2	100	100	100	-	97.7	45.5	81.8	100	90.9
	36	2024	-	-	0	88.9	97.2	-	100	100	-	97.2	47.2	88.6	100	91.7
K. pneumoniae	172	2025	0	84.3	81.3	92.4	92.4	98.6	95.9	100	100	93	23.3	94.2	95.3	87.8
	179	2024	0	83.2	90.5	91.1	93.3	-	97.2	100	100	93.9	19.6	97.8	94.4	85.5
P. aeruginosa	55	2025	-	-	-	-	87.3	-	90	94.7	94.7	87.3	-	98.1	100	-
	46	2024	-	-	-	-	84.8	-	95.7	95.7	95.7	82.6	-	95	100	-
P. mirabilis	98	2025	88.8	96.9	87.9	100	89.8	100	95.9	93.8	93.8	91.7	0	100	97.9	86.7
	92	2024	93.5	100	98.9	98.9	95.7	-	97.8	93.5	93.5	95.7	0	100	100	94.6
ESBL	11	2025	-	-	-	-	-	100	45.5	-	100	-	72.7	-	-	18.2

Non-Urine (Includes blood): Gram-Positive Cocci

	Tested	Year											
			Ampicillin	Benzylpenicillin	Chloramphen	Clindamycin	Erythromycin	Gentamicin	Oxacillin	Penicillin	Tetracycline	TMP-SMX	Vancomycin
S. aureus	81	2025	-	0	-	-	65.4	100	100	0	87.2	-	100
	102	2024	-	0	-	-	68.6	100	100	0	89.9	-	100
MRSA	87	2025	-	0	-	72.4	10.3	100	0	0	75.3	39.1	100
	95	2024	-	0	-	49.5	8.4	100	0	0	82.6	35.8	100
S. epidermidis	5	2025	-	0	-	-	20	100	60	0	100	-	100
	18	2024	-	0	-	-	33.3	100	22.2	0	77.8	-	100
S. pneumoniae	8	2025	-	-	100	-	87.5	-	100	100	50	-	100
	5	2024	-	-	100	-	80	-	100	100	75	100	100
E. faecalis	30	2025	100	97	-	-	-	Gent HS	Linezolid	Strepto HS	-	-	100
	39	2024	100	100	-	-	-				-	-	100
E. faecium	1	2025	100	100	-	-	-	Gent HS	Linezolid	Strepto HS	-	-	100
	4	2024	75	75	-	-	-				-	-	75
VRE	3	2025	33	33	100	-	-	100	100	100	-	-	0
	1	2024	0	0	-	-	-	100	100	100	-	-	0

Brattleboro Memorial Hospital Antimicrobial Susceptibility Report

Non-Urine (Includes blood): Gram-Negative Rods

	Tested	Year	Antimicrobials																
			Amox-Clav	Ampicillin	Amp-Sulb	Cefazolin	Ceftazidime	Ceftriaxone	Cefuroxime	Chloramphen	Ciprofloxacin	Ertapenem	Gentamicin	Imipenem	Levofloxacin	Meropenem	Pip-Taz	Tobramycin	TMP-SMX
E. coli	54	2025	-	66.7	79.6	83	-	92.6	-	-	81.5	100	94.4	100	81.5	100	94.4	87.9	87
	61	2024	-	62.9	78.7	90.2	-	93.4	-	-	93.4	-	95.1	100	93.4	-	91.8	95.1	85.2
K. pneumoniae	12	2025	-	0	83.3	-	-	91.7	-	-	91.7	100	91.7	100	91.7	100	93.3	100	91.7
	19	2024	-	0	63.2	73.7	-	73.7	-	-	84.2	-	100	100	84.2	-	94.4	84.2	68.4
P. mirabilis	17	2025	-	82.4	100	33.3	-	94.1	-	-	100	100	94.1	100	100	91.7	100	100	88.2
	33	2024	-	72.7	97	100	-	100	-	-	84.8	-	97	96.9	84.8	-	100	97	78.8
E. cloacae complex	14	2025	-	-	-	-	-	100	-	-	100	88.9	100	100	100	100	100	100	100
	10	2024	-	-	-	-	-	100	-	-	100	-	100	100	100	-	100	100	100
P. aeruginosa	25	2025	-	-	-	-	96	-	-	-	96	-	100	100	92	88.2	96	100	-
	13	2024	-	-	-	-	100	-	-	-	84.6	-	100	100	84.6	-	100	100	-
ESBL	11	2025	-	-	-	-	-	-	-	-	-	100	-	-	-	100	-	-	50
No Previous Year's Data																			
H. influenzae	3	2025	-	66.7	-	-	-	100	100	100	100	-	-	-	-	-	-	-	66.7
	3	2024	33.3	0	-	-	100	100	100	100	-	Minocycline	-	-	-	-	-	-	33.3
S. maltophilia	2	2025	-	-	-	-	-	-	-	-	-	100	100	-	-	-	-	-	100

Blood: Gram-Positive Cocci

	Tested	Year	Antimicrobials															
			Ampicillin	Benzylpenicillin	Chloramphen	Ciprofloxacin	Clindamycin	Erythromycin	Gentamicin	Gentamicin Hi-Syn	Levofloxacin	Linezolid	Oxacillin	Penicillin	Streptomycin Hi-Syn	Tetracycline	TMP-SMX	Vancomycin
E. faecalis	4	2025	100	100	-	-	-	-	-	-	-	-	100	-	-	-	100	
	1	2024	100	100	-	-	-	-	-	-	-	-	-	100	-	-	100	
E. faecium	1	2025	100	100	-	-	-	-	-	-	-	-	100	-	-	-	100	
	4	2024	75	75	-	-	-	-	-	-	-	-	75	-	-	-	75	
S. aureus	10	2025	-	0	-	60	-	30	100	-	-	-	100	0	-	90	-	100
	11	2024	-	0	-	100	-	63.6	100	-	-	-	100	0	-	81.8	-	100
MRSA	15	2025	-	0	-	13.3	73.3	0	100	-	-	-	0	0	-	73.3	20	100
	10	2024	-	0	-	0	50	0	100	-	-	-	0	0	-	77.8	20	100
S. epidermidis	3	2025	-	0	-	100	-	33.3	100	-	-	-	66.7	0	-	100	-	100
	4	2024	-	0	-	50	-	25	100	-	-	-	-	0	-	100	-	100
S. pneumoniae	8	2025	-	-	100	-	-	87.5	-	-	100	-	100	100	-	50	100	100
	4	2024	-	-	100	-	-	75	-	-	100	-	100	100	-	75	100	100
VRE	2	2025	50	100	100	-	-	0	0	100	-	100	-	-	100	-	-	0

Blood: Gram-Negative Rods

	Tested	Year	Antimicrobials													
			Ampicillin	Amp-Sulb	Cefazolin	Ceftazidime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin	Imipenem	Levofloxacin	Meropenem	Pip-Tazo	Tobramycin	TMP-SMX
E. coli	17	2025	59	82	77	-	94	82	100	100	100	82	100	100	100	82
	30	2024	60	70	97	-	97	93	-	93	100	93	-	97	93	83
K. pneumoniae	4	2025	0	50	-	-	75	75	100	75	100	75	100	50	100	75
	14	2024	0	79	86	-	86	79	-	100	100	79	-	93	86	79
P. mirabilis	3	2025	100	100	33	-	100	100	100	100	100	100	100	100	100	100
	5	2024	60	80	100	100	100	100	-	100	80	100	-	100	100	100
E. cloacae complex	3	2025	-	-	-	-	100	100	100	100	100	100	100	100	100	100
P. aeruginosa	5	2025	100	100	33	100	-	100	-	100	-	100	100	100	100	100
ESBL	11	2025	0	0	0	0	0	0	100	0	0	0	100	0	0	50